Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEG35156 and paclitaxel in advanced breast cancer
NCT00558545Phase 2Terminated
- Sponsor
- Aegera Therapeutics
- Start
- Nov 2007
- Primary completion
- May 2009
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label trial of AEG35156 in breast cancer, sponsored by Aegera Therapeutics. Primary endpoint: Recommended dose of AEG35156 at 2 years. Started Nov 2007; status: terminated.
02
Drugs
AEG35156
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00558545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00558545.